Can-Fite BioPharma Signs MOU With the Korean Company Kwang Dong Pharmaceutical for Licensing CF101 Rights for Korea

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange announced today that it has signed a Memorandum of Understanding with Kwang Dong Pharmaceutical Co., a Korean company, granting Kwang Dong exclusive rights to develop and commercialize the drug CF101 for the treatment of rheumatoid arthritis in Korea. CF101, Can-Fite’s lead drug, is currently being tested in multi-national Phase IIb study for its therapeutic activity in the treatment of rheumatoid arthritis and in two Phase IIa studies: one for the treatment of psoriasis and the other for dry eye syndrome.

MORE ON THIS TOPIC